Back to Browse Journals » Open Access Emergency Medicine » Volume 2

Treatment of patients with ethylene glycol or methanol poisoning: focus on fomepizole

Authors Bruno Mégarbane

Published Date August 2010 Volume 2010:2 Pages 67—75

DOI http://dx.doi.org/10.2147/OAEM.S5346

Published 26 August 2010

Bruno Mégarbane
Réanimation Médicale et Toxicologique, Hôpital Lariboisière and Université Paris-Diderot, Paris, France
Abstract: Ethylene glycol (EG) and methanol are responsible for life-threatening poisonings. Fomepizole, a potent alcohol dehydrogenase (ADH) inhibitor, is an efficient and safe antidote that prevents or reduces toxic EG and methanol metabolism. Although no study has compared its efficacy with ethanol, fomepizole is recommended as a first-line antidote. Treatment should be started as soon as possible, based on history and initial findings including anion gap metabolic acidosis, while awaiting measurement of alcohol concentration. Administration is easy (15 mg/kg-loading dose, either intravenously or orally, independent of alcohol concentration, followed by intermittent 10 mg/kg-doses every 12 hours until alcohol concentrations are <30 mg/dl). There is no need to monitor fomepizole concentrations. Administered early, fomepizole prevents EG-related renal failure and methanol-related visual and neurological injuries. When administered prior to the onset of significant acidosis or organ injury, fomepizole may obviate the need for hemodialysis. When dialysis is indicated, 1 mg/kg/h-continuous infusion should be provided to compensate for its elimination. Side-effects are rarely serious and with a lower occurrence than ethanol. Fomepizole is contraindicated in case of allergy to pyrazoles. It is both efficacious and safe in the pediatric population, but is not recommended during pregnancy. In conclusion, fomepizole is an effective and safe first-line antidote for EG and methanol intoxications.
Keywords: ethanol, hemodialysis, metabolic acidosis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Prevalence of HIV-related thrombocytopenia among clients at Mbarara Regional Referral Hospital, Mbarara, southwestern Uganda

Taremwa IM, Muyindike WR, Muwanguzi E, Boum II Y, Natukunda B

Journal of Blood Medicine 2015, 6:109-113

Published Date: 10 April 2015

Ultrastructural localization of intravenously injected carbon nanohorns in tumor

Matsumura S, Yuge R, Sato S, Tomida A, Ichihashi T, Irie H, Iijima S, Shiba K, Yudasaka M

International Journal of Nanomedicine 2014, 9:3499-3508

Published Date: 23 July 2014

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011

The first 7 years of the metropolitan fire brigade emergency responder program – an overview of incidents attended

Malcolm J Boyle, Brett Williams, Colin Bibby, et al

Open Access Emergency Medicine 2010, 2:77-82

Published Date: 11 October 2010

Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer

Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Federica Tomao, Silverio Tomao

International Journal of Nanomedicine 2009, 4:99-105

Published Date: 27 April 2009

Treprostinil for pulmonary hypertension

Nika Skoro-Sajer, Irene Lang, Robert Naeije

Vascular Health and Risk Management 2008, 4:507-513

Published Date: 30 June 2008

The history of barbiturates a century after their clinical introduction

Francisco López-Muñoz, Ronaldo Ucha-Udabe, Cecilio Alamo

Neuropsychiatric Disease and Treatment 2005, 1:329-343

Published Date: 18 February 2005